@article {Ekstr{\“o} m1902202,作者= {Ekstr {\ " o} m,马格努斯和约翰逊,j·米利暗黄,曹国伟和克鲁,David c .}, title ={最小平均临床重要差异,最好,最差和电流强度和不愉快的慢性呼吸困难},体积= {56}= {2},elocation-id = {1902202} = {2020}, doi ={10.1183/13993003.02202 -2019},出版商={欧洲呼吸学会},文摘={背景慢性呼吸困难造成了灾难性的后果。188bet官网地址电流强度的最小临床重要差异(MCID)在100-mm的视觉模拟评分(VAS)中被估计为9毫米。我们的目的是确定常用维度和回忆期的MCIDs:慢性呼吸困难过去24小时的当前不愉快程度和当前、平均、最佳和最差强度。方法:这是对由严重疾病引起的慢性呼吸困难患者进行的为期7天的吗啡与安慰剂随机对照试验的二次分析。每天晚上在100毫米VAS上使用日记自行报告呼吸困难评分。使用基于锚点和基于分布的方法估计每个评分中改进的MCID。283名参与者(平均年龄74.2岁;63 \ %的男性;58 \ %慢性阻塞性肺病;纳入87.0\%改良医学研究委员会(mMRC)评分3{\textendash}4)。基于锚的MCIDs的呼吸困难评分范围从-13.9毫米到-9.5毫米。使用不同锚点时，所有参与者以及呼吸困难较严重的参与者的mcid相似(mMRC 3{\textendash}4)。 Distribution-based effect sizes were classed as small (-4.7-6.3 mm), moderate (-9.4-12.5 mm) and large (-15.0-20.0 mm) effect. Sample sizes for trials using the different scores were proposed. MCIDs of absolute change were more stable than using relative change from baseline.Conclusion An improvement of \~{}10 mm on a 100-mm VAS is likely to be clinically meaningful across commonly used measures of chronic breathlessness (current intensity, unpleasantness, and average, best and worst intensity over the past 24 h) to evaluate clinical benefit and effects in therapeutic trials.This cohort study determined clinically important differences for current intensity and unpleasantness and the average, best and worst intensity of the past 24 h of chronic breathlessness, which is important for the design of therapeutic trials https://bit.ly/3amslss}, issn = {0903-1936}, URL = {//www.qdcxjkg.com/content/56/2/1902202}, eprint = {//www.qdcxjkg.com/content/56/2/1902202.full.pdf}, journal = {European Respiratory Journal} }